

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

### **POSITIVE PROFIT ALERT**

This announcement is published by the Company pursuant to the disclosure obligations under Rule 13.09(2) of the Listing Rules and Inside Information Provisions under Part XIVA of the SFO.

The Board hereby wishes to inform the Shareholders and potential investors that the Group is expecting to record a significant increase in the net profit for the six months ended 30 June 2016 in comparison with the corresponding period of 2015.

**The Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is published by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the disclosure obligations under Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) hereby wishes to inform shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2016 (the “**Management Accounts**”) and the information currently available to the Group, the Group is expecting to record a significant increase in the net profit for the six months ended 30 June 2016 in comparison with the corresponding period of 2015. Such expected increase is mainly attributable to the increase in the number of purchase orders placed by customers with the Group in the life sciences research service and preclinical drug development service segments, resulting from (i) the Group’s continuous efforts in constantly improving the

production efficiency for each existing service line, fast growing new and upgraded services and expanded customer base under the life sciences research service segment, and (ii) improvement of service delivery speed under the preclinical drug development service segment.

This positive profit alert announcement is only based on the preliminary assessment by the Board with reference to the Management Accounts and the information currently available, which is subject to finalization and adjustments where necessary, and has not been reviewed or audited by the Company's auditors or audit committee. The Company is still in the process of finalizing the unaudited interim results of the Group for the six months ended 30 June 2016. Financial information and other details of the Group will be disclosed in the unaudited interim results announcement of the Company for the six months ended 30 June 2016.

The Shareholders and potential investors are advised to read carefully the unaudited interim results announcement of the Company for the six months ended 30 June 2016, which will be published before the end of August 2016 pursuant to the requirements of the Listing Rules.

**The Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 15 July 2016

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin, and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.*

\* *For identification purposes only*